Director and Chief Executive Officer
United States of America
Dr. Truong is a founder of Aridis and recently elected to the CEO position in 2014 after having served as the company's Chief Scientific Officer for the past 9 years. He has over 15 years experience in biopharmaceutical drug development, having held positions of increasing responsibilities in companies which were eventually acquired by larger entities, including Gene Medicine (sold to Megabios), Aviron (sold to Medimmune), and Medimmune (sold to Astra Zeneca). He has a life-long interest and research experience in infectious diseases, focusing on the development of innovative human monoclonal antibodies and vaccines designed to address life threatening infections. His product development experience includes FluMist™, Synagis™ mAb, and a number of other monoclonal antibody based therapeutics. Dr. Truong is the principal architect of the Aridis technologies, which includes a range of anti-infective products and pharmaceutical processing technologies. He received his Ph.D. in Pharmacology and Molecular Sciences at the Johns Hopkins University School of Medicine.
biopharmaceutical drug development